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Abstract The covalent conjugation of oligonucleotides to anti-
body Fab’ fragments was optimized by using oligonucleotides
modified with a hexaethylene linker arm bearing three amino
groups. One oligonucleotide was coupled to antibody of one
specificity and a complementary oligonucleotide to antibody of a
second specificity. The antibodies were then allowed to hybridize
by base pairing of the complementary nucleotide sequences and
the generation of bispecific antibody was analyzed on SDS-
PAGE and confirmed using BIAcore analysis. The strategy of
complementary oligonucleotide-linked bispecific molecules is not
limited to antibodies but is applicable to linking any two
molecules of different characteristics.
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1. Introduction
An oligonucleotide-conjugated molecule has the potential
to spontaneously associate, via DNA base pairing, with any
other molecule to which the complementary oligonucleotide
sequence has been attached. Whilst oligonucleotides have pre-
viously been attached to both IgG and IgM antibody mole-
cules [1], the potential to link two antibodies via complemen-
tary base pairing has not previously been explored. Bispeci¢c
antibodies have potential uses in many areas including tumor
imaging and therapy, ligand immobilization, immunohisto-
chemistry and immunodiagnostics [2^5]. Three principal strat-
egies have been employed for their production: chemical
crosslinking, hybrid hybridomas and genetic engineering.
Chemical crosslinking can result in heterogeneous products
with batch to batch variation. The hybrid hybridoma ap-
proach generates various chain assortments requiring puri¢-
cation to isolate the desired bispeci¢c molecules. More re-
cently, recombinant bispeci¢c molecules have been
genetically engineered in various forms. For example, Neri
and colleagues [6] produced chelating recombinant antibodies
(CRAbs) utilizing a sequence encoding a polypeptide linker to
join two scFv molecules. Bispeci¢c molecules have also been
formed by crosslinking two di¡erent genetically engineered
Fab’s at their hinge sulfhydryls by using fos and jun leucine
zippers to facilitate heterodimerization [7]. The recombinant
DNA approach has the potential disadvantage that some im-
munoglobulin variable region sequences may be di⁄cult to
express as soluble recombinant proteins.
We have devized a novel method of making bispeci¢c anti-
bodies in which oligonucleotides are covalently linked to Fab’
fragments, the bispeci¢c antibodies then being formed by al-
lowing hybridization of complementary oligonucleotide-Fab’
conjugates. This approach is illustrated in a model system in
which two di¡erent anti-immunoglobulin reagents have been
linked together.
2. Materials and methods
2.1. Antibodies
Goat anti-human IgG (Q-chain-speci¢c) F(ab’)2 fragment (Sigma I-
9885) and sheep anti-mouse IgG (whole molecule) F(ab’)2 fragment
(Sigma M-1522) were purchased from Sigma (Poole, Dorset, UK).
The antigens for these anti-immunoglobulins were human IgG, ob-
tained as a 40% saturated ammonium sulfate precipitate from normal
human serum and dialyzed into 0.1 M phosphate-bu¡ered saline pH
7.4 (PBS), and mouse IgG, isolated from normal mouse serum by
protein G (Pharmacia Biotech, Uppsala, Sweden) puri¢cation.
2.2. Oligonucleotides
The complementary 15-mer oligonucleotides TCGATGCAAATC-
TAT and TAGATTTGCATCGAT were used (Oswel, Southampton,
UK), the latter synthesized with a 5P-terminal biotin. NH2-oligonu-
cleotides with one amino group at the 3P-end and a hexaethylene
linker-modi¢ed oligonucleotide with three amino groups attached at
the 3P-end [8] were investigated.
2.3. Production of Fab’-oligonucleotide conjugates
200 Wl of 955 WM amine-derivatized oligonucleotide was reacted in
the dark for 30 min at 20‡C with a 100-fold molar excess of the
crosslinking agent N-hydroxysuccinimidyl(4-iodoacetyl)aminoben-
zoate (SIAB, Pierce and Warriner, Chester, UK) in 0.1 M bicarbonate
bu¡er, pH 9.0. Activated oligonucleotide was separated from un-
reacted crosslinker by gel ¢ltration on a Sephadex G-25 PD10 column
(Pharmacia Biotech), equilibrated with 0.1 M phosphate bu¡er, pH
7.5, containing 10 mM ethylenediamine tetraacetic acid (EDTA).
500 Wl of 1.5 mg F(ab’)2 sheep anti-mouse IgG or F(ab’)2 goat anti-
human IgG was incubated with an equal volume of 0.1 M phosphate
bu¡er, pH 7.0, containing 10 mM EDTA and 20 mM 2-mercaptoeth-
ylamine at 37‡C for 30 min to cleave the inter-heavy chain disul¢de
bonds of the hinge region. Under these mild reducing conditions, the
disul¢de bonds between the heavy and light chains are preserved [9].
The resulting Fab’ fragments were concentrated and the 2-mercapto-
ethylamine removed, using a Centricon 10 spin column and washing
with PBS containing 10 mM EDTA.
A 7-fold molar excess of the relevant activated oligonucleotide in
0.1 M phosphate bu¡er, pH 7.5, 10 mM EDTA was incubated with
the concentrated Fab’ overnight at 4‡C. Fab’-oligonucleotide conju-
gate was puri¢ed by HPLC size exclusion chromatography using a
BioCad Sprint apparatus (PerSeptives, Hertford, UK) with a Bio-Sil
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SEC-125 column (Bio-Rad Laboratories, Hemel Hempstead, UK),
equilibrated with 25 mM Tris, 250 mM NaCl, pH 7.4 (Tris-bu¡ered
saline, TBS).
2.4. SDS-PAGE and immunoblotting
Conjugation reaction products were analyzed by both isoelectric
focusing using the PhastSystem with pre-formed IEF gels, pH range
3^9 (Pharmacia Biotech), and by SDS-PAGE in a Mini Protean Sys-
tem (Bio-Rad Laboratories). Transfer onto Hybond C nitrocellulose
membranes (Amersham International, UK) from SDS-PAGE was
carried out in 25 mM Tris, 192 mM glycine, pH 8.2, at 4‡C using
200 mA overnight. The blots were blocked using 0.1% Tween 20 and
3% dried milk powder in PBS and probed using horseradish peroxi-
dase (HRP)-conjugated donkey antibodies to either sheep Fab’ or
goat Fab’ (The Binding Site, Birmingham, UK) followed by detection
using enhanced chemiluminescence (ECL kit, Amersham). Mem-
branes were stripped using 50 mM glycine-HCl pH 2.7, washed in
PBS and re-probed with either streptavidin-HRP (DAKO, Denmark)
in PBS 0.05% Tween 20 (PBS-T) to detect biotinylated oligonucleo-
tides or with complementary biotinylated oligonucleotides in hybrid-
ization bu¡er (5USSC (750 mM NaCl, 75 mM sodium citrate, pH
7.4), 0.05% SDS, 10% w/v dextran sulfate, 5UDenhardts, 100 Wg/ml
salmon sperm DNA) to detect non-biotinylated oligonucleotide. In
the latter case, the membrane was pre-hybridized for 30 min in hy-
bridization bu¡er without oligonucleotide and then hybridized over-
night at 20‡C. Following hybridization with biotinylated oligonucleo-
tide, the membrane was washed three times at 20‡C, 37‡C or 55‡C
with 0.1% SDS in 2USSC, then with PBS and probed with strepta-
vidin-HRP.
For SDS-PAGE analysis of oligonucleotide-linked bispeci¢c anti-
body, 2 Wl of each of the two complementary Fab’-oligonucleotide
conjugates in TBS was allowed to hybridize at 20‡C for 15 min prior
to loading.
2.5. BIAcore analysis
The basic procedure for BIAcore (Biacore AB, Uppsala, Sweden)
analysis has been described before [10]. Mouse IgG was immobilized
on a CM5 BIAcore chip using the BIAcore AB amine coupling kit.
All reactions were carried out at 25‡C at a constant £ow rate of 10 Wl/
min. The matrix was activated by injecting 80 Wl of a 1:1 mixture of
11.5 mg/ml N-hydroxysuccinimide and 75 mg/ml N-ethyl-NP-(3-di-
methylaminopropyl)-carbodiimide to enable it to covalently bind
free amino groups of proteins. This was followed by a 60 Wl injection
of a 30 Wg/ml solution of mouse IgG in 10 mM acetate bu¡er, pH 4.5.
Any remaining unreacted sites were blocked with an injection of 40 Wl
of 1 M ethanolamine. Approximately 6500 resonance units (RU) were
immobilized. 5 Wl of each of the two Fab’-oligonucleotide conjugates
was mixed with 5 Wl TBS and left on ice for 15 min to form the
bispeci¢c antibody and then injected over the immobilized mouse
IgG (antigen 1) in running bu¡er (0.005% Tween 20 in PBS) at 10
Wl/min. This was followed by injection of human IgG (antigen 2) in
running bu¡er. To correct the drift due to dissociating conjugate, a
control injection of bu¡er alone was subtracted using the BIAevalua-
tion v3.0 software.
3. Results
3.1. Oligonucleotide conjugation to Fab’
The 3P-amino-linked oligonucleotides were reacted with the
heterobifunctional crosslinking agent SIAB, the NHS-ester
end of which reacts with the primary amine to produce a
iodoacetyl-activated oligonucleotide. The subsequent reaction
of the iodoacetyl group with protein containing free sulfhy-
dryls proceeds by nucleophilic substitution of iodine with a
thiol group, resulting in a stable thioether linkage. Optimum
reaction conditions for conjugation (pH 7.0^7.5) were initially
established using free cysteine. Separation on 10% acrylamide
sequencing gels of the oligonucleotide-cysteine conjugate in-
dicated that oligonucleotide with one 3P-linked primary amine
group gave a maximum of 50% conjugation with cysteine
whereas oligonucleotide modi¢ed with a hexaethylene linker
arm containing three amine groups showed almost 100% con-
jugation e⁄ciency. When the activated hexaethylene linker
arm-modi¢ed oligonucleotide was reacted with Fab’, the con-
jugation between Fab’ and oligonucleotide was speci¢c for the
hinge region at pH 7.0^7.5 when only cysteine groups are
reactive and non-speci¢c at pH 8.5 when lysine residues are
also reactive. An average of one oligonucleotide was attached
per Fab’ as calculated from the 260:280 nm absorbance ratio
of the conjugate following removal of free oligonucleotide by
gel ¢ltration and using the Beer’s equations according to
Kuijpers and colleagues [11]. Following conjugation with bio-
tinylated oligonucleotide, the Fab’ increased in size to 60 kDa.
The 60 kDa band was con¢rmed as being Fab’-oligonucleo-
tide conjugate by probing a Western blot with anti-sheep
Fab’-HRP, stripping with glycine-HCl bu¡er and re-probing
with streptavidin-HRP to detect the biotinylated oligonucleo-
tide (Fig. 1a, lanes 3 and 4). Covalent linkage of the oligonu-
cleotide to the Fab’ was con¢rmed using reducing SDS-PAGE
(Fig. 1b) in which bands of equal intensity were observed at
29 kDa and 38 kDa (intact light chain and oligonucleotide-
conjugated heavy chain fragment, respectively), whereas the
original F(ab’)2 gave only the 29 kDa band (unresolved intact
light chain and heavy chain fragment). The addition of a
highly negatively-charged DNA molecule should shift the iso-
electric point of the Fab’. Isoelectric focusing showed that the
pI of oligonucleotide alone was 3.7 and of unreacted F(ab’)2
was 5.2^9, whereas the Fab’-oligonucleotide conjugate gave
two broad bands with pI values of 4.5^5 and 5.3^6.5 (data
not shown).
3.2. Oligonucleotide-conjugated Fab’ is able to bind the
complementary oligonucleotide
A Western blot of the goat anti-human IgG Fab’-oligonu-
cleotide (non-biotinylated) was ¢rst probed with HRP-labelled
donkey anti-goat Fab’, stripped and then hybridized with bio-
tinylated complementary oligonucleotide and re-probed with
streptavidin-HRP. The calculated thermal stability of the hy-
bridized complex measured as the melting temperature, Tm,
Fig. 1. (a) Sheep anti-mouse IgG Fab’-oligonucleotide-biotin conju-
gates separated on non-reducing 10% SDS-PAGE gels. Lane 1, sil-
ver stain of the reaction mixture; lane 2, silver stain following puri-
¢cation of the conjugate by size exclusion chromatography; lane 3,
Western blot from a non-reducing 10% SDS-PAGE gel of puri¢ed
conjugate probed with donkey anti-sheep Fab’-HRP; lane 4, West-
ern blot of puri¢ed conjugate probed with streptavidin-HRP. (b)
Reducing 12% SDS-PAGE. Silver stain. lane 1, sheep anti-mouse
IgG Fab’-oligonucleotide-biotin conjugate; lane 2, sheep anti-mouse
IgG F(ab’)2.
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was 40‡C. Washing the hybridized blots at 20‡C or 37‡C
showed that the oligonucleotide remained hybridized. How-
ever, washing at 55‡C led to dissociation of the complemen-
tary oligonucleotide (results not shown).
3.3. Generation of bispeci¢c antibody
Hybridized Fab’-oligonucleotide conjugate pairs form a sta-
ble complex which is of a higher molecular weight than un-
modi¢ed F(ab’)2 (Fig. 2). The bispeci¢c antibody is able to
bind mouse IgG immobilized on a BIAcore chip (Fig. 3a) and
subsequently bind £uid phase human IgG (Fig. 3b). Binding
to the immobilized mouse IgG precludes the bispeci¢c anti-
body binding £uid phase mouse IgG. Dual speci¢city was also
observed using enzyme-linked immunosorbent assays (data
not shown).
4. Discussion
Conjugation of oligonucleotides to antibodies has previ-
ously been aimed at generating reagents with a therapeutic
potential such as the delivery of antisense sequences [11]. Oli-
gonucleotide can be conjugated to antibody Fab’ through the
reduced disul¢des of the hinge region, thus excluding the pos-
sibility of steric hindrance a¡ecting antigen binding. We now
show that antibodies may be linked together following con-
jugation of complementary oligonucleotides to the desired
Fab’ molecules and that the resulting hybridized complex is
able to bind to antigen in a bispeci¢c manner.
Oligonucleotide possessing a single available amine gave a
maximum of 50% conjugation, whereas the use of a hexaeth-
ylene linker arm with three amino groups led to an almost
100% conjugation e⁄ciency with an average of one oligonu-
cleotide molecule coupled to each Fab’ molecule. The major-
ity of the Fab’-oligonucleotide molecules produced in this way
were able to hybridize to complementary Fab’-oligonucleotide
to generate bispeci¢c antibody.
The Tm of the oligonucleotides was 40‡C and the bispeci¢c
antibodies remain hybridized at 37‡C. Thus, it might be fea-
sible to design bispeci¢c antibodies which would not normally
dissociate in vivo but would do so at sites of pyrexia, as
during an in£ammatory response during which temperatures
of 39^40‡C are reached [12]. This would then make the ex-
posed oligonucleotide available for hydrogen binding to a
more closely matched complementary oligonucleotide, if the
design of the original oligonucleotide pair contained slight
mismatches, or to a drug or other ligand able to target sin-
gle-stranded nucleic acid.
The utility of bispeci¢c antibodies against two di¡erent
antigens has already been demonstrated in a number of sit-
uations including the targeting of FcQR1 on cytotoxic myeloid
cells to the HER-2/neu proto-oncogene on tumor cells [13]
and of the T-cell receptor on cytotoxic T-cells to vesicular
stomatitis virus G protein on virus-infected cells [14]. Alter-
natively, dual epitope bispeci¢c antibodies recognizing two
non-overlapping epitopes on the same antigen would have
an increased avidity for the antigen [6,15]. The use of oligo-
nucleotides of a di¡erent chain length would introduce di¡er-
ent spacing between the Fab’s, so permitting optimization of
the binding kinetics. For in vivo use especially, it may be
advantageous to use peptide nucleic acids [16] in place of
DNA in order to minimize the susceptibility to nucleases
and to reduce the highly negative charge of DNA.
One novel feature of an antibody conjugated to an oligo-
nucleotide is that it contains two types of biological informa-
tion, namely, the antigen binding speci¢city of the antibody
and the nucleic acid sequence of the oligonucleotide. The use
Fig. 2. Non-reducing 8% SDS-PAGE gel illustrating hybridization
of the two oligonucleotide-Fab’ conjugates to generate the bispeci¢c
antibody. Silver stain. Lane 1, sheep anti-mouse IgG Fab’-oligonu-
cleotide-biotin conjugate; lane 2, oligonucleotide-linked bispeci¢c
antibody; lane 3, goat anti-human IgG Fab’-oligonucleotide conju-
gate; lane 4, goat anti-human IgG Fab’-oligonucleotide conjugate
plus complementary oligonucleotide; lane 5, sheep anti-mouse IgG
Fab’-oligonucleotide-biotin conjugate plus complementary oligonu-
cleotide; lane 6, sheep anti-mouse IgG F(ab’)2 ; lane 7, goat anti-hu-
man IgG F(ab’)2.
Fig. 3. (a) Passage of pre-formed oligonucleotide-linked bispeci¢c
antibody over mouse IgG immobilized on a BIAcore chip and (b)
subsequent passage of £uid phase human IgG or mouse IgG.
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of such dual information has previously been exploited in
antibody-directed PCR approaches [17]. In the current appli-
cation, the sequence information encoded in an oligonucleo-
tide-linked bispeci¢c antibody could potentially be utilized to
target a DNA binding protein. This could be generated as a
fusion protein with, for example, an enzyme catalyzing the
conversion of a pro-drug to a pharmacologically active com-
pound. Oligonucleotide linkage to create dual or multispeci¢c
molecules is not limited to antibodies but can be utilized to
connect any two molecules such as lectins, hormones, cyto-
kines or adhesion molecules.
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